MarketResearchReports.Biz presents this most up-to-date research on " EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023 "
A market intelligence report has recently been added by MarketResearchReports.biz to its vast repository of research studies. The report, titled “EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast To 2023,” provides a thorough analysis, emphasizing on the major risk factors, comorbidities, and the current trends in the market. The study helps the readers in formulating effective business strategies by considering the trends influencing and propelling the global market for renal cell carcinoma (RCC) market.
Furthermore, the research study has made use of tables, charts, and graphics to present the diagnosis of RCC at clinical stage and the risk factors for the growth for this condition. The epidemiology report on renal cell carcinoma provides inputs given by industry experts to offer a clear understanding of the overall market.
Renal cell carcinoma is a type of kidney cancer in which the cancer cells are formed in the tubules of the kidney. A tubule is a part of the small tubes present in the kidney, which carries the waste molecules from the blood till urine. In the initial stages, renal cell carcinoma exhibits no major symptoms, due to which most patients are already at an advanced stage when they discover the condition. Some of the key symptoms of RCC are flank pain, weight loss, night sweats, blood in the urine, hypertension, a mass in the flank or abdomen, fever, and a general feeling of being sick.
Kidney cancer has been reported to be one of the most frequently occurring types of cancers in Western countries in the last few years. According to the research study, in 2013, there were around 186,179 incident cases of renal cell carcinoma in the major eight geographical segments, including France, Japan, Italy, the U.S., Spain, Germany, urban China, and the U.K. The number of incident cases is projected to rise 6.25% in the next few years and reach 302,449 cases. In 2013, the prevalent cases of renal cell carcinoma in the eight major markets were 593,228. Each of the regional markets is expected to witness a significant rise in the prevalent cases throughout the forecast period.
Some of the prominent players such as F. Hoffmann-La Roche, Ltd., Pfizer, Inc., Novartis AG, Bayer AG, and GlaxoSmithKline, plc are developing novel drugs and therapeutics in order to treat patients with renal cell carcinoma condition. The rising incidence of renal cell carcinoma across the major markets is expected to be a result of growing use of imaging techniques to detect tumors.
The research study has classified the global market renal cell carcinoma on the basis of age and sex. The historical information and forecast data of the incidence cases have been presented in the research report. In addition, detailed evaluation of the major regional segments has also discussed in the report. Furthermore, the major players operating in the market are making efforts to develop new and innovative products, enhance the product structure, and reduce the pricing.